Search

Your search keyword '"Ilaria Iacobucci"' showing total 488 results

Search Constraints

Start Over You searched for: Author "Ilaria Iacobucci" Remove constraint Author: "Ilaria Iacobucci"
488 results on '"Ilaria Iacobucci"'

Search Results

51. Data from Phase Separation Mediates NUP98 Fusion Oncoprotein Leukemic Transformation

52. Supplementary Table from Phase Separation Mediates NUP98 Fusion Oncoprotein Leukemic Transformation

53. Supplementary Data from Integrated Genomic Analysis Identifies UBTF Tandem Duplications as a Recurrent Lesion in Pediatric Acute Myeloid Leukemia

54. Supplementary Data from Phase Separation Mediates NUP98 Fusion Oncoprotein Leukemic Transformation

55. Supplementary Data from ZNF384 Fusion Oncoproteins Drive Lineage Aberrancy in Acute Leukemia

56. Supplementary Figure from Integrated Genomic Analysis Identifies UBTF Tandem Duplications as a Recurrent Lesion in Pediatric Acute Myeloid Leukemia

57. Data from Enhancer Hijacking Drives Oncogenic BCL11B Expression in Lineage-Ambiguous Stem Cell Leukemia

58. Supplementary Tables from Enhancer Hijacking Drives Oncogenic BCL11B Expression in Lineage-Ambiguous Stem Cell Leukemia

59. Supplementary Figures, and Supplementary Table Legends from Enhancer Hijacking Drives Oncogenic BCL11B Expression in Lineage-Ambiguous Stem Cell Leukemia

60. Supplementary Figures S1-S4 from The Combination of the PARP Inhibitor Rucaparib and 5FU Is an Effective Strategy for Treating Acute Leukemias

61. Data from The Combination of the PARP Inhibitor Rucaparib and 5FU Is an Effective Strategy for Treating Acute Leukemias

62. Supplementary Methods, Tables 1-7, Figures 1-4 from CDKN2A/B Alterations Impair Prognosis in Adult BCR-ABL1–Positive Acute Lymphoblastic Leukemia Patients

63. Supplementary Figure S2 from Prospective Phase II Study on 5-Days Azacitidine for Treatment of Symptomatic and/or Erythropoietin Unresponsive Patients with Low/INT-1–Risk Myelodysplastic Syndromes

64. Data from Targeting CDK6 and BCL2 Exploits the 'MYB Addiction' of Ph+ Acute Lymphoblastic Leukemia

65. Data from CDKN2A/B Alterations Impair Prognosis in Adult BCR-ABL1–Positive Acute Lymphoblastic Leukemia Patients

66. Data from Prospective Phase II Study on 5-Days Azacitidine for Treatment of Symptomatic and/or Erythropoietin Unresponsive Patients with Low/INT-1–Risk Myelodysplastic Syndromes

68. Supplementary Table S1 from Prospective Phase II Study on 5-Days Azacitidine for Treatment of Symptomatic and/or Erythropoietin Unresponsive Patients with Low/INT-1–Risk Myelodysplastic Syndromes

69. Supplementary Figures and Legends from Targeting CDK6 and BCL2 Exploits the 'MYB Addiction' of Ph+ Acute Lymphoblastic Leukemia

71. Supplementary Table 2 from Protein Tyrosine Phosphatase Receptor Type γ Is a Functional Tumor Suppressor Gene Specifically Downregulated in Chronic Myeloid Leukemia

72. Data from Protein Tyrosine Phosphatase Receptor Type γ Is a Functional Tumor Suppressor Gene Specifically Downregulated in Chronic Myeloid Leukemia

73. Supplementary Table 1 from Protein Tyrosine Phosphatase Receptor Type γ Is a Functional Tumor Suppressor Gene Specifically Downregulated in Chronic Myeloid Leukemia

74. Comprehensive Genome Characterization of Childhood T-ALL Links Oncogene Activation Mechanism and Subtypes to Prognosis

75. Integrated Genomic Analysis Identifies UBTF Tandem Duplications as a Recurrent Lesion in Pediatric Acute Myeloid Leukemia

76. Glucosyl Platinum(II) Complexes Inhibit Aggregation of the C-Terminal Region of the Aβ Peptide

77. Ruthenium complexes bearing glucosyl ligands are able to inhibit the amyloid aggregation of short Histidine-peptides

78. KMT2A-rearranged leukemia: the shapeshifter

79. Therapeutic potential of ruxolitinib and ponatinib in patients with EPOR-rearranged Philadelphia chromosome-like acute lymphoblastic leukemia

80. Enhancer Hijacking Drives Oncogenic BCL11B Expression in Lineage-Ambiguous Stem Cell Leukemia

81. Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia

82. Protein–DNA/RNA Interactions: An Overview of Investigation Methods in the -Omics Era

83. Modeling and targeting of erythroleukemia by hematopoietic genome editing

85. Histone Acetyltransferases Are Critical Interacting Proteins in NUP98-Rearranged Acute Myeloid Leukemia

86. 72. Variant curation of BCR::ABL1-like B-lymphoblastic leukemia/lymphoma through expert panel consensus

87. ZNF384 Fusion Oncoproteins Drive Lineage Aberrancy in Acute Leukemia

88. Mutational landscape and patterns of clonal evolution in relapsed pediatric acute lymphoblastic leukemia

89. BMP2/SMAD pathway activation in JAK2/p53-mutant megakaryocyte/erythroid progenitors promotes leukemic transformation

90. A09 ADAM10 activity at the huntington’s disease presynapse

91. Poster: AML-158 Phase Separation Mediates NUP98 Fusion Oncoprotein Leukemic Transformation

92. AML-283 The Genetic Landscape of NUP98-Rearranged Pediatric Leukemia

93. Poster: AML-283 The Genetic Landscape of NUP98-Rearranged Pediatric Leukemia

95. The genomic landscape of pediatric acute lymphoblastic leukemia

96. Long-chain polyphosphates impair SARS-CoV-2 infection and replication

97. What Antarctic Plants Can Tell Us about Climate Changes: Temperature as a Driver for Metabolic Reprogramming

98. Germline deletion of ETV6 in familial acute lymphoblastic leukemia

99. Genetic Alterations and Therapeutic Targeting of Philadelphia-Like Acute Lymphoblastic Leukemia

100. Lysosome purinergic receptor P2X4 regulates neoangiogenesis induced by microvesicles from sarcoma patients

Catalog

Books, media, physical & digital resources